Antireflux surgery and risk of esophageal adenocarcinoma : a systematic review and meta-analysis by Maret-Ouda, John et al.
ANNSURG-D-14-01960; Total nos of Pages: 7;
ANNSURG-D-14-01960
META-ANALYSISAntireflux Surgery and Risk of Esophageal Adenocarcinoma:
and Meta-analysisA Systematic ReviewJohn Maret-Ouda, MD, Peter Konings, MSc, Jesper Lagergren, MD, PhD,y
and Nele Brusselaers, MD, MSc, PhDObjective: To investigate the preventive effect of antireflux surgery against
esophageal adenocarcinoma (EAC) compared with medical treatment of
gastroesophageal reflux disease (GERD) and to the background population.
Background: GERD is causally associated with EAC. Effective symptomatic
treatment can be achieved with medication and antireflux surgery; however
the possible preventive effect on EAC development remains unclear.
Methods: This systematic review identified 10 studies comparing EAC risk
after antireflux surgery with nonoperated GERD patients, including 7 studies
of patients with Barrett’s esophagus, and 2 studies comparing EAC risk after
antireflux surgery to the background population. A fixed-effects Poisson
meta-analysis was conducted to calculate pooled incidence rate ratios (IRR)
and 95% confidence intervals (CI).
Results: The pooled IRR in patients after antireflux surgery was 0.76 (95%
CI 0.42–1.39) compared with medically treated GERD patients. In patients
with Barrett’s esophagus, the corresponding IRR was 0.46 (95% CI 0.20–
1.08), and 0.26 (95% CI 0.09–0.79) when restricted to publications after
2000. There was no difference in EAC risk between antireflux surgery and
medical treatment in GERD patients without known Barrett’s esophagus (IRR
0.98, 95% CI 0.72–1.33). The EAC risk remained elevated in patients after
antireflux surgery compared with the background population (IRR 10.78,
95% CI 8.48–13.71). Although the clinical heterogeneity of the included
studies was high, the statistical heterogeneity was low.
Conclusions: Antireflux surgery may prevent EAC better than medical
therapy in patients with Barrett’s esophagus. The EAC risk after antireflux
surgery does not seem to revert to that of the background population.
Keywords: cancer, gastroesophageal reflux, incidence, neoplasm, prevention
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astroesophageal reflux disease (GERD) is a strong and dose-Copyright © 2015 Wolters Kluwer Health, Inc. U
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Annals of Surgery  Volume XX, Number X, Month 2015(EAC).1,2 The incidence of EAC has increased rapidly in theWestern
world during the last 4 decades, and the prognosis has remained poor
(<15% survival in Western societies).3,4 Thus, preventive measures
are highly warranted. Antireflux therapy might be one such measure,
but the available literature is limited and has failed to establish any
conclusive preventive effects against EAC. The main treatment
options for severe GERD are medical [mainly proton pump inhibitors
(PPI) or H2 receptor antagonists] or surgical (various types of
fundoplication).5–7 Two previous meta-analyses of patients with
GERD and Barrett’s esophagus found no preventive effect of anti-
reflux surgery in the development of EAC compared with medical
treatment.8,9 However, both these meta-analyses included studies
evaluating only one treatment and pooled the medically treated
patients in one group and the surgically treated patients in another.
This could lead to methodological difficulties when comparing any
preventive effects.8,9 A third, more recent meta-analysis concluded
that antireflux surgery does not prevent EAC in patients with
Barrett’s esophagus based on a high postoperative tumor progression
rate.10 The first objective of the current study was to perform a
systematic review and meta-analysis comparing the risk of EAC in
patients after antireflux surgery compared with medically treated
patients with GERD, with or without Barrett’s esophagus, and only
include studies with both treatment arms. The second objective was
to assess the risk of EAC after antireflux surgery compared with the
risk of EAC in the corresponding background population.
METHODS
Study Design
A systematic literature review and meta-analysis was per-
formed, which followed a priori established study protocol. The
results are reported in accordance with the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analysis) guide-
lines.11 The search aimed to identify all studies addressing the risk of
EAC after antireflux surgery compared with medication in patients
with GERD, with and without Barrett’s esophagus, or compared with
the background population. All definitions of GERD and antireflux
surgery were considered eligible for inclusion and no language
restriction was applied. The time period was from an unbounded
start date to June 12, 2014. Three scientific search engines were used:
PubMed/MedLine database, Web of Science, and Cochrane. To
identify relevant studies, the following search terms were used:
esophageal, esophagus, neoplasm, adenocarcinoma, cancer, Barrett,
fundoplication, antireflux surgery, Nissen, and reflux surgery (taking
into account different spellings). Backward and forward citation
tracking of the identified studies was performed by screening refer-
ence and citation lists in the Web of Science to identify potential
additional articles. The selection of relevant articles was performed
by two investigators separately after which all selected articles were
compared. The final assessment of the eligibility of the articles
remaining after exclusion of irrelevant articles was performed bynauthorized reproduction of this article is prohibited.
all authors.
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Studies were included if they provided original data on the
incidence of EAC in patients with GERD undergoing surgical treat-
ment compared with medically treated patients with GERD (with or
without Barrett’s esophagus), or the corresponding general back-
ground population. To increase statistical power, no restrictions were
made regarding type of antireflux medication or antireflux surgery
procedure. To be included, the study needed to have reported the type
of intervention performed in each comparison group, the incidence of
EAC in each group, and the total follow-up time (reported or
deductible) to enable calculation of incidence rates. Any patients
developing high-grade dysplasia were included in the EAC group. To
be eligible for inclusion, there had to be at least one reported case of
EAC in one or both of the comparison groups. Eligible studies
included cohort studies, case-control studies, and intervention studies
(randomized clinical trials), and both prospective and retrospective
studies. Case reports, case series, cross-sectional studies, and non-
original articles (eg, reviews, editorials, and comments) were
excluded, along with animal studies and those without a comparison
group. A quality assessment of the included articles was based on theCopyright © 2015 Wolters Kluwer Health, Inc. Un
methods of selecting study participants, methods for measuring the
2 | www.annalsofsurgery.comexposure and outcome, sources of bias, methods for controlling for
potential confounding, and conflicts of interests.12
Data Synthesis and Statistical Analysis
The total number of person-years of the comparison groups
were either calculated or extracted from the selected articles. The
meta-analysis was conducted using the R package metaphor.13,14 A
fixed-effects Poisson meta-analysis was used to calculate the pooled
incidence rate ratio (IRR) and 95% confidence intervals (CI).15 The
IRR was considered statistically significant if the 95% CI did not
include the number 1, which corresponds with no effect. In the
statistical model, the studies were weighted because of the size of the
cohorts. A random effects Poisson meta-analysis showed similar
results as the fixed-effects Poisson meta-analysis. The included
studies were separated into two groups: (1) antireflux surgery
compared with a medicated GERD population with and without
Barrett’s esophagus and (2) antireflux surgery compared with the
corresponding background population. In studies where one of the
treatment arms had no cases of EAC, we added 0.5 to both treatment
arms, an established method described in detail elsewhere.15 In theauthorized reproduction of this article is prohibited.
two included studies using the background population as a
FIGURE 1. Search strategy used in this
systematic review and numbers of
eligible studies in each stage.
 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Annals of Surgery  Volume XX, Number X, Month 2015 Antireflux Surgery and Esophageal Cancercomparison group, no follow-up time was stated for the background
population. For one study, the total incidence of EAC for the back-
ground population was stated, whereas for the other study this
information was retrieved from the authors who provided additional
data on the background population. Using the incidence and the
incidence rate, a total follow-up time could be calculated.16,17
Statistical heterogeneity was assessed by means of an I2 test and
was categorized into low (<50%), moderate (51%–75%), or high
(>75%) according to predefined criteria.18
RESULTS
Included Studies
Among a total of 1987 unique articles that were considered, 12
met the inclusion criteria (Fig. 1). These included seven cohort
studies comparing EAC risk in patients after antireflux surgery with
a medically treated GERD population,19–25 one cohort study com-
paring EAC risk in patients after antireflux surgery without specified
treatment in a GERD population,26 two randomized clinical trials
comparing EAC risk in patients after antireflux surgery with medi-
cated GERD patients,27,28 and two population-based studies compar-
ing EAC risk in GERD patients undergoing antireflux surgery to the
background population.16,17 Of the 10 studies with nonoperated
GERD patients as a control group, seven included patients with
Barrett’s esophagus.19–22,24,25,28 The mean follow-up time varied
across studies, ranging from 1.4 years to 10.6 years (up to 42 years).
The clinical heterogeneity in the included studies was large as
indicated in the quality assessment presented in Fig. 2.
Definitions
GERD and antireflux surgery were identified based on the
International Classification of Diseases (ICD) versions 7–10 in 3
studies,17,23,26 whereas one study used the American Joint Commit-
tee of Cancer (AJCC) criteria for these variables.16 The seven studies
of Barrett’s esophagus were all based on endoscopic and pathologic
evaluation.19–22,24,25,28 Nissen fundoplication (360 degree wrap of
the stomach around the esophagus) was the most frequently usedCopyright © 2015 Wolters Kluwer Health, Inc. U
surgical procedure. In the medication groups, PPI or H2-receptor
FIGURE 2. Characteristics and quality assessment of all 12 includ
nonmedicated patients as comparison.
 2015 Wolters Kluwer Health, Inc. All rights reserved.antagonists were typically used, although three studies did not
specify the type of medication (Table 1).
Antireflux Surgery Patients Versus Nonoperated
Patients with GERD or Barrett’s Esophagus
The 10 studies in this categorywere performed in theUS, Spain,
Sweden, Ireland, and the United Kingdom, and included a total of
100,479 person-years in patients after antireflux surgery and 403,459
person-years in nonoperated GERD patients (Table 1). None of the
individual studies showed any statistically significant differences in
risk of EAC among patients after antireflux surgery and medically
treated GERD patients, but the IRRs of EAC were generally lower in
the antireflux surgery groups (Fig. 3). The meta-analysis of all 10
studies revealed a pooled IRR of EAC of 0.89 (95% CI 0.66–1.19, I2
0%) comparing fundoplication with no fundoplication (Fig. 3). After
excluding the one study comparing patients after antireflux surgery
with a GERD population without known treatment, the corresponding
pooled IRR decreased (IRR 0.76, 95% CI 0.42–1.39, I2 0%). The
analysis of the seven studies of patients with Barrett’s esophagus
showed a decreased pooled IRRof EAC in the antireflux surgery group
compared with the medically treated group (IRR 0.46, 95% CI 0.20–
1.08, I2 0%). The subanalysis restricted to the four studies of Barrett’s
esophagus published after the year 2000 showed a further decreased
risk of EAC after antireflux surgery compared with medication (IRR
0.26, 95% CI 0.09–0.79, I2 0%), which reached the threshold of
statistical significance. An analysis of three studies investigating
GERD patients without confirmed Barrett’s esophagus showed no
difference in EAC risk between antireflux surgery and medical treat-
ment (IRR 0.98, 95% CI 0.72–1.33, I2 0%). The statistical hetero-
geneity in all analyses was low (I2¼ 0%). Subgroup analyses by
different types of medication, surgical techniques, or study designs
were not feasible because of the limited number of studies meeting the
inclusion criteria.
Antireflux Surgery Patients Versus Background
Population
Two nationwide and population-based cohort studies, fromnauthorized reproduction of this article is prohibited.
Sweden and Finland, compared the risk of developing EAC in
ed studies in this meta-analysis. Excluding three studies with
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TABLE 1. Included Studies, Number of Patients, Total Follow-up Times, and Number of Cases of Esophageal Adenocarcinoma
(EAC) in This Meta-analysis
Reference Year Country
Type of
study
No of
patients
Type of
surgery
Type of
medication
Follow-up
(person-years)
Mean (max)
follow-up
in years
HGD/
EAC
Lagergren
et al
2010 Sweden Population-
based
14102 ARS NF, partial fundo-
plication
N/A 120,514 8.5 (42) 0/39
Kauttu et al 2011 Finland Population-
based
17643 ARS NF/partial fundo-
plication, Roux-
en-Y reconstruc-
tion
N/A 134,438 7.6 (unknown) 0/29
Williamson
et al
1990 US Cohort 37 ARS NF, Collis gastro-
plasty
N/A 144 3.9 (unknown) 0/3
142 MT 198 1.4 (unknown) 0/2
McCallum
et al
1991 US Cohort 29 ARS; 152
MT
NF, Hill gastro-
pexy, Belsey
procedure
N/A 150; 621 5.2 (unknown);
4.1 (unknown)
0/0
0/2
Attwood et al 1992 Ireland Cohort 19 ARS Partial anterior
fundoplication
H2RA 57; 78 3 (9); 3 (9) 0/1; 0/1
26 MT
Spechler et al 2001 US Randomized
controlled study
71 ARS; 137
MT
NF H2RA, PPI, meto-
clopramide,
sucralfate
646; 1452 9.1 (unknown);
10.6 (unknown)
0/1; 0/4
Ye et al 2001 Sweden Cohort 11077 ARS N/A Unknown 86996 7.8 (unknown) 0/43
66965 UR 376622 5.7 (unknown) 0/200
Gurski et al 2003 US Cohort 77 ARS NF, partial fundo-
plication
PPI 323 4.2 (unknown) 3/0
14 MT 59 4.2 (unknown) 1/0
Parrilla et al 2003 Spain Randomized
controlled study
58 ARS NF, Collis–Nis-
sen procedure
PPI 406 7 (18) 2/0
43 MT 258 6 (18) 2/0
Oberg et al 2005 Sweden Cohort 46 ARS; 94
MT
NF, Hill gastro-
pexy, partial fun-
doplication
H2RA, PPI 347; 599 7.5 (11.5); 6.4
(8.2)
0/0; 6/1
Tran et al 2005 US Cohort 946 ARS Fundoplication N/A 11156 11.8 (unknown) 0/8
1892 MT 20115 10.6 (unknown) 0/8
Gatenby et al 2009 UK Cohort 41 ARS N/A H2RA, PPI 254 6.19 (unknown) 0/0
697 MT 3457 4.96 (unknown) 10/20
ARS indicates antireflux surgery; H2RA, H2-receptor-antagonist; HGD, high grade dysplasia; MT, medical treatment; N/A, not applicable; NF, Nissen fundoplication; PPI, proton
pump inhibitors; RCT, randomized controlled trial.
Maret-Ouda et al Annals of Surgery  Volume XX, Number X, Month 2015patients after antireflux surgery to that of the background population
after adjustment for age, sex, and calendar period.16,17 The maximum
follow-up times were 42 years and 26 years, in the Swedish and
Finnish studies, respectively. Combining these two studies, the total
number of person-years of follow-up was 254,952 and 166,060,651
in the antireflux surgery group and in the background population,
respectively. Both studies showed a strongly increased relative risk of
EAC after antireflux surgery that remained increased with longer
time after surgery, and the meta-analysis revealed a pooled stand-
2ardized IRR of 10.78 (95% CI 8.48–13.71, I 0%) (Fig. 4).DISCUSSION
This meta-analysis provided some evidence of a decreased
risk of EAC in patients after antireflux surgery compared with
medicated patients with Barrett’s esophagus, but not in GERD
patients without Barrett’s. The risk of EAC remained elevated in
patients after antireflux surgery compared with that of the general
background population.
A methodological advantage of this study is that it includedCopyright © 2015 Wolters Kluwer Health, Inc. Un
only studies with two separate treatment arms, instead of including
4 | www.annalsofsurgery.commultiple studies with only one treatment arm. This makes compari-
sons more reliable, as potential confounding is to some extent taken
into account because of a similar clinical setting in the comparison
groups. Weaknesses include the fact that none of the included studies
adjusted for duration or severity of GERD. However, the comparison
groups should have been well balanced regarding confounders in the
two intervention studies because of randomization. The statistical
heterogeneity was low (I2 was 0% in all analyses). However, there
was a large clinical heterogeneity, as the study characteristics varied
considerably. As with any meta-analysis, we cannot exclude the
possibility that studies were missed during our search, or that studies
that observed null effects were never published (publication bias).
Potential influence related to changes in surgical treatment, prescrip-
tion patterns of GERDmedication, or duration of follow-up could not
be assessed because of the lack of such data. In the clinical setting,
there might have been selection bias in the decision making, as
clinicians might be more prone to recommend antireflux surgery to
patients with more severe GERD and therefore an inherently higher
risk of EAC. However, such bias would underestimate any protective
effect of antireflux surgery against EAC and not contribute to theauthorized reproduction of this article is prohibited.
decreased risk compared with medication, indicated in the current
 2015 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 3. Forrest plot comparing the
risk of esophageal adenocarcinoma after
antireflux surgery and medical treatment
in patients with gastroesophageal reflux
disease with and without Barrett’s esoph-
agus. FE indicates fixed-effects.
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exposure and outcome were pooled together, but again, such mis-
classification would dilute effects rather than cause them, and could
thus lead to an underestimation of the decreased IRRs after antireflux
surgery. Finally, the low number of studies, the typically small
sample size, and limited follow-up time in the included studies
lowered the statistical power and increased the risk of chance errors.
The CIs were wide and even strongly decreased risk estimates were
not always statistically significant.
In relation to previous meta-analyses on the subject, our meta-
analysis had more strict inclusion criteria and used different method-
ology. One meta-analysis only reported the incidence of EAC in
patients with Barrett’s esophagus after antireflux surgery and medi-
cation separately, as 3.8/1000 person-years and 5.3/1000 person-years,
respectively, concluding that no difference was found.8 However, the
equivalent of this risk ratio was in fact 0.72 (calculated by us).
Moreover, 24 of the 34 articles included in that study had only one
treatment arm. In amore recentmeta-analysis that compared the risk of
EAC after antireflux surgery withmedication in patients with Barrett’s
9Copyright © 2015 Wolters Kluwer Health, Inc. U
esophagus, 20 of 25 included articles had one treatment arm only. The
FIGURE 4. Forrest plot comparing antireflux surgery to an
unselected corresponding background population and risk of
esophageal adenocarcinoma in this meta-analysis. FE indicates
fixed-effects.
 2015 Wolters Kluwer Health, Inc. All rights reserved.incidence rate after surgery was 2.8/1000 person-years and 6.3/1000
person-years after medical treatment.9 This is equivalent to a risk ratio
as low as 0.44 (calculated by us). In the most recent meta-analysis,
published in 2008, 35 articles examining the risk of EAC in operated
patients without any comparison group concluded that antireflux
surgery does not prevent EAC based on a tumor progression rate of
3.8% during a mean follow-up time of 57 months.10
Except for the decreased pooled risk estimates of EAC in
patients after antireflux surgery compared with medication in
patients with Barrett’s esophagus, another argument in favor of a
protective effect of antireflux surgery against EAC is that the recent
studies all showed an effect size in the same direction. However to
establish whether any preventive effect against EAC is better after
antireflux surgery than medication, there is a need for larger studies
with long follow-up and adjustment for confounders that take
duration and severity of GERD into account. As mentioned above,
there is a risk of selection bias in the included studies. Such a bias
would be more prone towards recommending surgery to patients with
more severe GERD who are at higher risk of EAC at baseline, and
this might lead to an underestimation of the possible preventive effect
of surgery compared with medication. As this would lead to an
underestimation of the effect in the meta-analysis as well, the chance
of a stronger preventive effect after antireflux surgery cannot be
excluded based on the available data.
Although medication came out as being less effective than
antireflux surgery in preventing EAC, this study cannot exclude a
preventive effect of medication. Although individual studies have
mostly failed to detect any preventive effect of medication against
EAC, a recent meta-analysis found a pooled odds ratio as low as 0.29
(95% CI 0.12–0.79) comparing patients on PPI with unspecified
non-PPI-users.29
The reasons for the potentially stronger preventive role ofnauthorized reproduction of this article is prohibited.
antireflux surgery for EAC compared with medication include the
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contents included in the refluxed juice, along with duodenogastroe-
sophageal reflux of bile and pancreatic juice, which could be
particularly harmful from a carcinogenic point of view.30 Medical
treatment does not prevent such reflux per se, but mainly decreases
the acidity of the refluxate. Moreover, a recent 5-year follow-up of a
randomized clinical trial using pH-measurements showed a lower
level of pathologic acidity in the esophagus after surgery compared
with medication in GERD patients.31 Finally, compared with medi-
cation, fundoplication is not dependent on dosage or compliance.
In this study, the risk of developing EAC remained elevated in
patients undergoing antireflux surgery compared with that of the
background population. This could be explained by a particularly
high severity of GERD in patients selected for antireflux surgery,
where the DNA is already damaged, leaving the operated patients at a
long-term increased risk of EAC compared with the population at
large. Moreover, the prevalence of Barrett’s esophagus is certainly
higher in the antireflux surgery group than in the general population,
and the Barrett’s mucosa does not disappear despite effective treat-
ment of GERD. Furthermore, some of the patients undergoing
antireflux surgery will have recurrence of GERD, again increasing
the risk of EAC compared with the background population.23,32,33
Although, it might be that a reduction of the risk to that of the
background population is not a reasonable goal because of the fact
that many patients already have a premalignant condition. However,
this is seldom the goal of other disease preventive measurements,
where the aim usually is a risk reduction compared with alternative
therapies or no treatment, rather than a reduction to the level of the
background population.
This meta-analysis suggests that antireflux surgery could be
beneficial for patients with Barrett’s esophagus from a cancer
preventive perspective, although uncertainty remains. A recent
Cochrane review34 concluded that both health-related quality of life
and GERD-specific quality of life are improved after surgery com-
pared with medication. Future research will show whether antireflux
surgery should be recommended more frequently, for example, to
young patients with Barrett?s esophagus. Especially if severity of
dysplasia and therefore future risk of EAC can be assessed (through
either gastroscopy and pathology, or biochemistry), a population
where there is a stronger EAC preventive effect could be identified.
Performing a randomized clinical trial large enough to assess and
compare the risk of EAC after surgery and medication would mean
large methodological, logistic, and ethical difficulties. Therefore,
other study designs, such as cohort studies or matched cohorts, might
be more feasible.
In conclusion, this systematic review and meta-analysis pro-
vide some evidence that antireflux surgery may prevent EAC better
than medication in patients with Barrett’s esophagus, whereas no
such association was found for GERD patients without Barrett’s. An
increased risk of EAC seems to remain long after antireflux surgery
compared with the background population, whichmight be as a result
of higher prevalence of Barrett’s esophagus. These results must be
interpreted cautiously as they are based on a limited sample size and
might be affected by bias from severity and duration of GERD,
confounding and chance errors. Hence there is a need for larger
studies with longer follow-up that take confounding and severity of
GERD into account, either by pathologic or molecular assessment
of severity.
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